A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Overview
The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.
Full Title of Study: “A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI)”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: April 2009
Detailed Description
The primary objective of the study was to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth. The secondary objective of the study was to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources. The safety objective of the study was to evaluate the safety of two dose levels of Naglazyme in infants under the age of one year who have MPS VI.
Interventions
- Drug: Naglazyme
- Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
Arms, Groups and Cohorts
- Other: Naglazyme, 1.0 mg/kg
- Dose comparison
- Other: Naglazyme, 2.0 mg/kg
- Dose Comparison
Clinical Trial Outcome Measures
Primary Measures
- Change in Height
- Time Frame: 52 weeks
- Change in Weight
- Time Frame: 52 weeks
- Change in Haed Circumference
- Time Frame: 52 weeks
Secondary Measures
- Change in Urinary Glycosaminoglycan Levels
- Time Frame: minimum 52 weeks of dosing
- Change in urinary GAG levels was calculated from baseline to week 52 of treatment.
Participating in This Clinical Trial
Inclusion Criteria
- Signed informed consent by a parent or legal guardian – Parent or legal guardian willing and able to comply with all study procedures – Equal to or greater than 36 weeks estimated gestational age by physical exam at birth – Has a diagnosis of MPS VI based on a documented prenatal diagnosis or fibroblast or leukocyte N-acetylgalactosamine 4-sulfatase (ASB) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory – Is less than one year of age – Has no evidence of skeletal dysplasia based on physical exam Exclusion Criteria:
- Parent of legal guardian perceived to be unreliable or unavailable for study participation – Use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments – Has concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation) – Any condition that, in the view of the principle investigator, renders the subject at high risk from treatment compliance and/or completing the study – Has known hypersensitivity to Naglazyme – Has previously received Naglazyme
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 1 Year
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- BioMarin Pharmaceutical
- Provider of Information About this Clinical Study
- Celeste Decker, MD, BioMarin Pharmaceutical Inc.
- Overall Official(s)
- Celeste Decker, MD, Study Director, BioMarin Pharmaceutical
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.